Reports Q2 revenue $593,000, consensus $1.21M. “The past few months have been a period of strong execution for Absci (ABSI), and we are positioned to build on this momentum,” said Sean McClain, Founder and CEO. “ABS-101 is advancing through clinical trials, ABS-201 is on track to enter the clinic early next year, and we recently announced a key milestone in our collaboration with Almirall. With a strengthened balance sheet and runway into the first half of 2028, we are well positioned to deliver on our mission.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- AbSci Corp options imply 11.5% move in share price post-earnings
- Absci Corp. (ABSI) Q2 Earnings Cheat Sheet
- Largest borrow rate increases among liquid names
- CRSP, ABSI, IRDM: Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Buys Absci and Iridium
- Absci price target lowered to $6.40 from $7 at Morgan Stanley